Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bromhexine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control Trial

Tolouian et al., SSRN, doi:10.2139/ssrn.3989
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 33% Improvement Relative Risk Hospitalization 70% Symp. case 53% Case 50% Bromhexine  Tolouian et al.  Prophylaxis  DB RCT Is prophylaxis with bromhexine beneficial for COVID-19? Double-blind RCT 372 patients in Iran (December 2020 - July 2021) Fewer symptomatic cases (p=0.007) and cases (p=0.028) c19early.org Tolouian et al., SSRN, December 2021 Favorsbromhexine Favorscontrol 0 0.5 1 1.5 2+
PEP RCT with 372 close contacts of COVID+ patients, 187 treated with bromhexine, showing significantly lower cases with treatment. IRCT20120703010178N22.
Bromhexine efficacy may vary depending on the degree of TMPRSS-dependent fusion for different variants1,2.
risk of death, 32.9% lower, RR 0.67, p = 0.76, treatment 0 of 187 (0.0%), control 1 of 185 (0.5%), odds ratio converted to relative risk, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 70.3% lower, RR 0.30, p = 0.14, treatment 1 of 187 (0.5%), control 6 of 185 (3.2%), adjusted per study, odds ratio converted to relative risk.
risk of symptomatic case, 53.0% lower, RR 0.47, p = 0.007, treatment 16 of 187 (8.6%), control 34 of 185 (18.4%), NNT 10, odds ratio converted to relative risk.
risk of case, 50.2% lower, RR 0.50, p = 0.03, treatment 13 of 187 (7.0%), control 26 of 185 (14.1%), NNT 14, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tolouian et al., 20 Dec 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, preprint, 16 authors, study period 21 December, 2020 - 25 July, 2021.
This PaperBromhexineAll
Bromhexine, for post exposure COVID-19 prophylaxis: A Randomized, Double-Blind, Placebo Control Trial
Ramin Tolouian, MD Omid Moradi, Zuber D Pharmd, Mulla, PhD Shadi Ziaie, Mehrdad Pharmd, Haghighi, MD Hadi Esmaily, Hossein Pharmd, Amini, PharmD Rezvan Hassanpour, Elham Pharmd, Pourheidar, Mehran Pharmd, Kouchek, MD Alireza Manafi-Rasi, MD Shahnaz Sali, MD Sara Abolghasemi, MD Shabnam Tehrani, MD Audrey C Tolouian, PharmD Mohammad Sistanizad
Background: Limited number of medications are available for the post-exposure prophylaxis of COVID-19 infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Methods: A multi-center randomized; double-blind, placebo-controlled clinical trial was conducted. The 372 adults (≥18 years) who had close contact within 4 days with a household member with confirmed COVID-19 were randomly assigned to receive bromhexine (n=187) or placebo (n=185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included the incidence of hospitalization or death, the incidence of confirmed COVID-19 detection by PCR in symptomatic patients and presence of adverse drug reactions. Findings: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs 34 [18.4%], relative risk=0.47, p=0.005). PCRconfirmation was reported in 13 (7.0%) and 26 (14.1%) of the individuals in the bromhexine and placebo groups, respectively (p=0.025), with a relative risk reduction of 50%. The hospitalization rate, death and medication side effects did not vary significantly between the bromhexine or placebo arms. Interpretation: Bromhexine is an effective, non-invasive, and affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection and hence it can play a prominent role in ending the pandemic especially given the emergence of new variants and the vaccination challenges faced by developing countries.
References
Anand, Puranik, Aravamudan, Venkatakrishnan, Soundararajan, SARS-CoV-2 strategically mimics proteolytic activation of human ENaC, Elife
Ansarin K, Tolouian, Ardalan, Taghizadeh, Varshochi, Teimouri, Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial, BioImpacts
Bartoszko, Siemieniuk, Kum, Qasim, Zeraatkar et al., Prophylaxis against covid-19: living systematic review and network meta-analysis, BMJ
Bernal, Andrews, Gower, Gallagher, Simmons et al., Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant, N Engl J Med
Bernal, Andrews, Gower, Robertson, Stowe et al., Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study, BMJ
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med
Fernandez, Mulla, Avoiding sparse data bias: an example from gynecologic oncology, Journal of registry management
Garten, Braden, Arendt, Peitsch, Baron et al., Influenza virus activating host proteases: Identification, localization and inhibitors as potential therapeutics, Eur J Cell Biol
Greenland, Modeling and variable selection in epidemiologic analysis, Am J Public Health
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell
Jackson, Farzan, Chen, Choe, Mechanisms of SARS-CoV-2 entry into cells, Nat Rev Mol Cell Biol
Jahromi, Mazloom, Ballard, What the European and American health care systems can learn from China COVID-19 epidemic; action planning using purpose designed medical telecommunication, courier services, home-based quarantine, and COVID-19 walk-in-centers, Immunopathol Persa
Mikhaylov, Vakhrushev, Stepanov, Lebedev, Vasilieva, Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study2021
O'brien, Forleo-Neto, Musser, Chan, Sarkar, Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19, N Engl J Med
Ou, Mou, Zhang, Ojha, Choe et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLoS Pathog
Pocock, Clinical Trials: A Practical Approach
Rossier, Stutts, Activation of the epithelial sodium channel (ENaC) by serine proteases, Annu Rev Physiol
Shei, Peabody, Kaza, Rowe, The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis, Curr Opin Pharmacol
Tolouian, Tolouian, Ardalan, Blocking serine protease (TMPRSS2) by Bromhexine; looking at potential treatment to prevent COVID-19 infection, Marshall Journal of Medicine
Vahed, Ghiyasvand, Tolouian, Noshad, Tolouian et al., The footprint of androgen sensitive serine protease (TMPRSS2) in gender mortality with COVID-19, Immunopathol Persa
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review, JAMA
Zanasi, Mazzolini, Kantar, A reappraisal of the mucoactive activity and clinical efficacy of bromhexine, Multidisciplinary respiratory medicine
Zumla, Chan, Azhar, Hui, Yuen, Coronaviruses -drug discovery and therapeutic options, Nat Rev Drug Discov
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit